“…262,264,265 The demonstration of the gene-editing potential of the CRISPR/Cas9 system has been demonstrated in the context of HD, [266][267][268][269] Alzheimer's disease (AD), 270,271 fragile X syndrome, 272 Parkinson's disease, 273,274 schizophrenia, 275 and neural stem cell gene repression, 276 among others, both in vitro and in vivo. The in vivo potential of the CRISPR/Cas9 system for brain applications has been confirmed in mice, 266,[268][269][270]272,276 rats 277,278 and monkeys 279 via intracerebral 266,[268][269][270][271][272]275,280 and intrathecal 275 administrations. Neurons, 270,272,277,[281][282][283] microglia, 272 neural stem/ progenitor cells, 276,283 and astrocytes 272 in animal models at embryonic, 280,284 fetal, and adult 270,…”